--- title: "PRL-8-53: Dosing & Vendor Prices — BodyHackGuide" description: "PRL-8-53: dosing protocols, mechanism & side effects. Compare 1 verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "PRL-8-53" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "PRL-8-53", "description": "PRL-8-53 is a benzoic acid ester with a benzylmethylamino side chain, first described by N. R. Hansl in a 1974 note in Experientia that presented it as a spasmolytic and central nervous system active agent studied in animals (PMID: 4824605). It is an outlier among the compounds sold as nootropics: almost everything claimed for it traces back to a single small human study published in 1978, and there has been essentially no follow-up research in nearly fifty years. That 1978 study, by Hansl and Mead in Psychopharmacology, tested the effect of low oral doses on learning and retention of verbal information under double-blind conditions using the serial anticipation method. The authors reported slight improvement of acquisition and statistically significant improvement of retention of verbal information, with most p values better than 0.01 and some better than 0.001, and no significant change in visual reaction time or motor control compared with placebo (PMID: 418433). PubMed indexes it as a randomized controlled trial. It was never replicated, and the widely repeated claim that volunteers doubled their memory comes from secondary retellings of subgroup results rather than from an independent trial. Searching PubMed for the acronym PRL-8-53 returns exactly one record, the 1978 human study. There is no published pharmacokinetic study, no repeat-dose toxicology, no receptor binding profile, no modern animal replication and no registered clinical trial. The mechanism is therefore unknown. The compound is a substituted phenethylamine derivative, and the 1974 report described central activity in animals alongside effects on blood pressure and interactions with apomorphine and methamphetamine, but no target has been identified and no mechanistic paper exists. Any confident mechanistic statement about PRL-8-53, including the frequently repeated claims about dopamine, acetylcholine or GABA, is not supported by published primary literature. The material sold to consumers is the hydrochloride salt, which is what the chemistry values on this page describe; the free base has a molecular weight of 283.4 g/mol (PubChem CID 39989). Purity and identity of the powder on the research chemical market have never been the subject of a published analysis, which matters more for a compound with one 47-year-old study behind it than for one with a modern regulatory dossier. PRL-8-53 has never been approved as a medicine in any jurisdiction, has never entered formal drug development, is not a controlled substance in the United States and has no established safe exposure level in humans. It should be read as a historical curiosity with an unusually strong reputation relative to the evidence supporting it, not as a characterized drug. Anyone weighing the compound should treat the total absence of safety data as the central fact about it.", "url": "https://www.bodyhackguide.co/compound/prl-8-53", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "64.99", "highPrice": "64.99", "priceCurrency": "USD", "offerCount": "1", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "64.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/prl-8-53/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" } } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "PRL-8-53", "description": "PRL-8-53 is a benzoic acid ester with a benzylmethylamino side chain, first described by N. R. Hansl in a 1974 note in Experientia that presented it as a spasmolytic and central nervous system active agent studied in animals (PMID: 4824605). It is an outlier among the compounds sold as nootropics: almost everything claimed for it traces back to a single small human study published in 1978, and there has been essentially no follow-up research in nearly fifty years. That 1978 study, by Hansl and Mead in Psychopharmacology, tested the effect of low oral doses on learning and retention of verbal information under double-blind conditions using the serial anticipation method. The authors reported slight improvement of acquisition and statistically significant improvement of retention of verbal information, with most p values better than 0.01 and some better than 0.001, and no significant change in visual reaction time or motor control compared with placebo (PMID: 418433). PubMed indexes it as a randomized controlled trial. It was never replicated, and the widely repeated claim that volunteers doubled their memory comes from secondary retellings of subgroup results rather than from an independent trial. Searching PubMed for the acronym PRL-8-53 returns exactly one record, the 1978 human study. There is no published pharmacokinetic study, no repeat-dose toxicology, no receptor binding profile, no modern animal replication and no registered clinical trial. The mechanism is therefore unknown. The compound is a substituted phenethylamine derivative, and the 1974 report described central activity in animals alongside effects on blood pressure and interactions with apomorphine and methamphetamine, but no target has been identified and no mechanistic paper exists. Any confident mechanistic statement about PRL-8-53, including the frequently repeated claims about dopamine, acetylcholine or GABA, is not supported by published primary literature. The material sold to consumers is the hydrochloride salt, which is what the chemistry values on this page describe; the free base has a molecular weight of 283.4 g/mol (PubChem CID 39989). Purity and identity of the powder on the research chemical market have never been the subject of a published analysis, which matters more for a compound with one 47-year-old study behind it than for one with a modern regulatory dossier. PRL-8-53 has never been approved as a medicine in any jurisdiction, has never entered formal drug development, is not a controlled substance in the United States and has no established safe exposure level in humans. It should be read as a historical curiosity with an unusually strong reputation relative to the evidence supporting it, not as a characterized drug. Anyone weighing the compound should treat the total absence of safety data as the central fact about it.", "lastReviewed": "2026-09-07T04:48:27.623Z", "url": "https://www.bodyhackguide.co/compound/prl-8-53", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "PRL-8-53", "alternateName": [ "PRL 8-53", "PRL8-53", "Methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate hydrochloride", "3-(2-benzylmethylaminoethyl)benzoic acid methyl ester hydrochloride" ], "description": "PRL-8-53 is a benzoic acid ester with a benzylmethylamino side chain, first described by N. R. Hansl in a 1974 note in Experientia that presented it as a spasmolytic and central nervous system active agent studied in animals (PMID: 4824605). It is an outlier among the compounds sold as nootropics: almost everything claimed for it traces back to a single small human study published in 1978, and there has been essentially no follow-up research in nearly fifty years. That 1978 study, by Hansl and Mead in Psychopharmacology, tested the effect of low oral doses on learning and retention of verbal information under double-blind conditions using the serial anticipation method. The authors reported slight improvement of acquisition and statistically significant improvement of retention of verbal information, with most p values better than 0.01 and some better than 0.001, and no significant change in visual reaction time or motor control compared with placebo (PMID: 418433). PubMed indexes it as a randomized controlled trial. It was never replicated, and the widely repeated claim that volunteers doubled their memory comes from secondary retellings of subgroup results rather than from an independent trial. Searching PubMed for the acronym PRL-8-53 returns exactly one record, the 1978 human study. There is no published pharmacokinetic study, no repeat-dose toxicology, no receptor binding profile, no modern animal replication and no registered clinical trial. The mechanism is therefore unknown. The compound is a substituted phenethylamine derivative, and the 1974 report described central activity in animals alongside effects on blood pressure and interactions with apomorphine and methamphetamine, but no target has been identified and no mechanistic paper exists. Any confident mechanistic statement about PRL-8-53, including the frequently repeated claims about dopamine, acetylcholine or GABA, is not supported by published primary literature. The material sold to consumers is the hydrochloride salt, which is what the chemistry values on this page describe; the free base has a molecular weight of 283.4 g/mol (PubChem CID 39989). Purity and identity of the powder on the research chemical market have never been the subject of a published analysis, which matters more for a compound with one 47-year-old study behind it than for one with a modern regulatory dossier. PRL-8-53 has never been approved as a medicine in any jurisdiction, has never entered formal drug development, is not a controlled substance in the United States and has no established safe exposure level in humans. It should be read as a historical curiosity with an unusually strong reputation relative to the evidence supporting it, not as a characterized drug. Anyone weighing the compound should treat the total absence of safety data as the central fact about it.", "activeIngredient": "PRL-8-53", "administrationRoute": "Oral", "mechanismOfAction": "Unknown. No target identification, receptor binding profile or mechanistic study has been published for PRL-8-53 in any species. The 1974 report by Hansl described the compound as a spasmolytic and central nervous system active agent and examined it in animal experiments alongside apomorphine and methamphetamine challenges and cardiovascular measures, but proposed no molecular mechanism (PMID: 4824605). The 1978 human study reported improved retention of verbal information without change in visual reaction time or motor control and did not investigate mechanism (PMID: 418433). Structurally the molecule is a substituted phenethylamine bearing a methyl benzoate group, which has prompted speculation about monoaminergic activity, but no binding, functional or microdialysis data have been published to support that or any other proposal.", "dosageForm": "capsule", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is PRL-8-53 used for in research?", "acceptedAnswer": { "@type": "Answer", "text": "PRL-8-53 is a benzoic acid ester with a benzylmethylamino side chain, first described by N. R. Hansl in a 1974 note in Experientia that presented it as a spasmolytic and central nervous system active agent studied in animals (PMID: 4824605). It is an outlier among the compounds sold as nootropics: almost everything claimed for it traces back to a single small human study published in 1978, and there has been essentially no follow-up research in nearly fifty years. That 1978 study, by Hansl and Mead in Psychopharmacology, tested the effect of low oral doses on learning and retention of verbal information under double-blind conditions using the serial anticipation method. The authors reported slight improvement of acquisition and statistically significant improvement of retention of verbal information, with most p values better than 0.01 and some better than 0.001, and no significant change in visual reaction time or motor control compared with placebo (PMID: 418433). PubMed indexes it as a randomized controlled trial. It was never replicated, and the widely repeated claim that volunteers doubled their memory comes from secondary retellings of subgroup results rather than from an independent trial. Searching PubMed for the acronym PRL-8-53 returns exactly one record, the 1978 human study. There is no published pharmacokinetic study, no repeat-dose toxicology, no receptor binding profile, no modern animal replication and no registered clinical trial. The mechanism is therefore unknown. The compound is a substituted phenethylamine derivative, and the 1974 report described central activity in animals alongside effects on blood pressure and interactions with apomorphine and methamphetamine, but no target has been identified and no mechanistic paper exists. Any confident mechanistic statement about PRL-8-53, including the frequently repeated claims about dopamine, acetylcholine or GABA, is not supported by published primary literature. The material sold to consumers is the hydrochloride salt, which is what the chemistry values on this page describe; the free base has a molecular weight of 283.4 g/mol (PubChem CID 39989). Purity and identity of the powder on the research chemical market have never been the subject of a published analysis, which matters more for a compound with one 47-year-old study behind it than for one with a modern regulatory dossier. PRL-8-53 has never been approved as a medicine in any jurisdiction, has never entered formal drug development, is not a controlled substance in the United States and has no established safe exposure level in humans. It should be read as a historical curiosity with an unusually strong reputation relative to the evidence supporting it, not as a characterized drug. Anyone weighing the compound should treat the total absence of safety data as the central fact about it." } }, { "@type": "Question", "name": "What forms does PRL-8-53 come in?", "acceptedAnswer": { "@type": "Answer", "text": "PRL-8-53 is available in capsule form." } }, { "@type": "Question", "name": "How much does PRL-8-53 cost?", "acceptedAnswer": { "@type": "Answer", "text": "Prices start at $64.99 across 1 verified vendor." } }, { "@type": "Question", "name": "How do I compare PRL-8-53 vendors?", "acceptedAnswer": { "@type": "Answer", "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Fprl-8-53) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. PRL-8-53 [Where to buy PRL-8-53](/buy/prl-8-53) [PRL-8-53 coupon codes](/coupons/prl-8-53) [PRL-8-53 protocol](/protocol/prl-8-53) [Alternatives to PRL-8-53](/alternatives-to/prl-8-53) [PRL-8-53 side effects](/side-effects/prl-8-53) 1. [Home](/) 3. [Compounds](/compare) 5. PRL-8-53 ![PRL-8-53 molecular structure](/assets/peptide-structure-placeholder-DUmZBF_j.png) # PRL-8-53 Nootropics Discontinued Download PDF Also known as: PRL 8-53, PRL8-53, Methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate hydrochloride, 3-(2-benzylmethylaminoethyl)benzoic acid methyl ester hydrochloride PRL-8-53 is a benzoic acid ester with a benzylmethylamino side chain, first described by N. R. Half-Life: Not established. No pharmacokinetic study in humans or in any animal species has been published for PRL-8-53. Route: Oral MW: 319.83 g/mol (hydrochloride salt) CAS: 51352-87-5 Last reviewed: Sep 7, 2026 [ Nootropics Category ](/wiki#cat-nootropics) Discontinued Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare Prices1 Related ## Overview ### Best Price Available ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $64.99 60 capsules · capsule [Buy Now](https://disguisedalpha.com/product/prl-8-53/?coupon=reddit) Compare 1 vendor ### At A Glance Mechanism Unknown. No target identification, receptor binding profile or mechanistic study has been published for PRL-8-53 in any species. The 1974 report by Hansl described the compound as a spasmolytic and central nervous system active agent and examined it in animal experiments alongsid… Half-Life Not established. No pharmacokinetic study in humans or in any animal species has been published for PRL-8-53. Routes Oral Potential Benefits Improved retention of verbal information in a double-blind study in human subjects using the serial anticipation method, with most p values better than 0.01 (PMID: 418433) Produced slight improvement of acquisition of verbal material in the same human study (PMID: 418433) Produced no change in visual reaction time or motor control compared with placebo in human subjects, which argues against a general stimulant effect (PMID: 418433) Described as centrally active in animal experiments in the original 1974 report (PMID: 4824605) ### Overview PRL-8-53 is a benzoic acid ester with a benzylmethylamino side chain, first described by N. R. Hansl in a 1974 note in Experientia that presented it as a spasmolytic and central nervous system active agent studied in animals (PMID: 4824605). It is an outlier among the compounds sold as nootropics: almost everything claimed for it traces back to a single small human study published in 1978, and there has been essentially no follow-up research in nearly fifty years. That 1978 study, by Hansl and Mead in Psychopharmacology, tested the effect of low oral doses on learning and retention of verbal information under double-blind conditions using the serial anticipation method. The authors reported slight improvement of acquisition and statistically significant improvement of retention of verbal information, with most p values better than 0.01 and some better than 0.001, and no significant change in visual reaction time or motor control compared with placebo (PMID: 418433). PubMed indexes it as a randomized controlled trial. It was never replicated, and the widely repeated claim that volunteers doubled their memory comes from secondary retellings of subgroup results rather than from an independent trial. Searching PubMed for the acronym PRL-8-53 returns exactly one record, the 1978 human study. There is no published pharmacokinetic study, no repeat-dose toxicology, no receptor binding profile, no modern animal replication and no registered clinical trial. The mechanism is therefore unknown. The compound is a substituted phenethylamine derivative, and the 1974 report described central activity in animals alongside effects on blood pressure and interactions with apomorphine and methamphetamine, but no target has been identified and no mechanistic paper exists. Any confident mechanistic statement about PRL-8-53, including the frequently repeated claims about dopamine, acetylcholine or GABA, is not supported by published primary literature. The material sold to consumers is the hydrochloride salt, which is what the chemistry values on this page describe; the free base has a molecular weight of 283.4 g/mol (PubChem CID 39989). Purity and identity of the powder on the research chemical market have never been the subject of a published analysis, which matters more for a compound with one 47-year-old study behind it than for one with a modern regulatory dossier. PRL-8-53 has never been approved as a medicine in any jurisdiction, has never entered formal drug development, is not a controlled substance in the United States and has no established safe exposure level in humans. It should be read as a historical curiosity with an unusually strong reputation relative to the evidence supporting it, not as a characterized drug. Anyone weighing the compound should treat the total absence of safety data as the central fact about it. ### Potential Research Fields Memory and retention Historical nootropics Research chemicals ## Chemical Information IUPAC Name Not yet available CAS Number 51352-87-5 Molecular Formula C18H22ClNO2 Molecular Mass 319.83 g/mol (hydrochloride salt) ![PRL-8-53 molecular structure](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/70700868/PNG) [View on PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/70700868) ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications None established. No toxicology, drug interaction, pregnancy, lactation, hepatic impairment or renal impairment data have been published for PRL-8-53 in humans or in animals. The only human exposure on record is a single 1978 study (PMID: 418433). With no pharmacokinetic profile and no repeat-dose data, there is no evidence base from which to define who should avoid it, which is itself a reason for caution. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $64.99 Best $/mg — Vendors 1 Listings 1 capsule [Sign in for alerts ](/auth) Form Allcapsule Sort Price $/mg Vendor Vendor Product Form Qty Price $/mg Coupon ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) [Disguised Alpha](/vendor/disguised-alpha) [50 ](/vendor-trust-scorecard) 🇺🇸 US 🇪🇺 EU 🇬🇧 UK PRL-8-53 capsules (60) capsule 60 capsules ● In Stock $64.99 BEST — — [Buy](https://disguisedalpha.com/product/prl-8-53/?coupon=reddit) Get PRL-8-53 Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. Current lowest: $64.99 [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with PRL-8-53. [Sign in](/auth) Current low $64.99 as of Sep 7, 2026 7-day low $64.99 30-day low $64.99 30-day change — baseline building Tracking since Sep 7, 2026 · 1 data point ### Vendors Selling PRL-8-53 [ ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) #### Disguised Alpha 1 listing · from $64.99 ](/vendor/disguised-alpha) How we score these vendors Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. [View Scorecard](/vendors/scorecard) ### Related Compounds [View All](/wiki) [ ### 9-Me-BC (9-Methyl-β-carboline) Nootropics Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\]. t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 6 studies View Profile ](/compound/9-mbc)[ ### Aniracetam Nootropics Approved (Italy) Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057. t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694). Preclinical View Profile ](/compound/aniracetam)[ ### Bemethyl (bemitil) Nootropics Approved (Russia) Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt. t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773) Preclinical View Profile ](/compound/bemethyl)[ ### Bromantane Nootropics Russia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. 34 studies View Profile ](/compound/bromantane)[ ### Cyclazodone Nootropics Preclinical Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. Preclinical View Profile ](/compound/cyclazodone)[ ### Dihexa Nootropics Preclinical Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose) 1 studies View Profile ](/compound/dihexa) [ View Full Dosage Guide → Protocols, calculator & safety for PRL-8-53 ](/guides/dosage/prl-8-53) ### Best Price ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $64.99 [Buy Now](https://disguisedalpha.com/product/prl-8-53/?coupon=reddit) 1 vendors · 1 listings ### Research Score 30 0 PubMed studies ### Quality Indicators Data Completeness 63% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings ### Quick Facts Half-Life Not established. No pharmacokinetic study in humans or in any animal species has been published for PRL-8-53. Molecular Weight 319.83 g/mol (hydrochloride salt) Administration Oral CAS Number 51352-87-5 Trial Phase Discontinued 0 [Full Dosage Guide](/guides/dosage/prl-8-53)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is PRL-8-53 used for in research? PRL-8-53 is a benzoic acid ester with a benzylmethylamino side chain, first described by N. R. Hansl in a 1974 note in Experientia that presented it as a spasmolytic and central nervous system active agent studied in animals (PMID: 4824605). It is an outlier among the compounds sold as nootropics: almost everything claimed for it traces back to a single small human study published in 1978, and there has been essentially no follow-up research in nearly fifty years. That 1978 study, by Hansl and Mead in Psychopharmacology, tested the effect of low oral doses on learning and retention of verbal information under double-blind conditions using the serial anticipation method. The authors reported slight improvement of acquisition and statistically significant improvement of retention of verbal information, with most p values better than 0.01 and some better than 0.001, and no significant change in visual reaction time or motor control compared with placebo (PMID: 418433). PubMed indexes it as a randomized controlled trial. It was never replicated, and the widely repeated claim that volunteers doubled their memory comes from secondary retellings of subgroup results rather than from an independent trial. Searching PubMed for the acronym PRL-8-53 returns exactly one record, the 1978 human study. There is no published pharmacokinetic study, no repeat-dose toxicology, no receptor binding profile, no modern animal replication and no registered clinical trial. The mechanism is therefore unknown. The compound is a substituted phenethylamine derivative, and the 1974 report described central activity in animals alongside effects on blood pressure and interactions with apomorphine and methamphetamine, but no target has been identified and no mechanistic paper exists. Any confident mechanistic statement about PRL-8-53, including the frequently repeated claims about dopamine, acetylcholine or GABA, is not supported by published primary literature. The material sold to consumers is the hydrochloride salt, which is what the chemistry values on this page describe; the free base has a molecular weight of 283.4 g/mol (PubChem CID 39989). Purity and identity of the powder on the research chemical market have never been the subject of a published analysis, which matters more for a compound with one 47-year-old study behind it than for one with a modern regulatory dossier. PRL-8-53 has never been approved as a medicine in any jurisdiction, has never entered formal drug development, is not a controlled substance in the United States and has no established safe exposure level in humans. It should be read as a historical curiosity with an unusually strong reputation relative to the evidence supporting it, not as a characterized drug. Anyone weighing the compound should treat the total absence of safety data as the central fact about it. What forms does PRL-8-53 come in? PRL-8-53 is available in capsule form. How much does PRL-8-53 cost? Prices start at $64.99 across 1 verified vendor. How do I compare PRL-8-53 vendors? Compare prices, payment methods, shipping, and COA scores across 1 vendor. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### 9-Me-BC (9-Methyl-β-carboline) Nootropics Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\]. t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 6 studies View Profile ](/compound/9-mbc)[ ### Aniracetam Nootropics Approved (Italy) Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057. t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694). Preclinical View Profile ](/compound/aniracetam)[ ### Bemethyl (bemitil) Nootropics Approved (Russia) Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt. t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773) Preclinical View Profile ](/compound/bemethyl)[ ### Bromantane Nootropics Russia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. 34 studies View Profile ](/compound/bromantane)[ ### Cyclazodone Nootropics Preclinical Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. Preclinical View Profile ](/compound/cyclazodone)[ ### Dihexa Nootropics Preclinical Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose) 1 studies View Profile ](/compound/dihexa) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-prl-8-53) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋